Login to Your Account



EntreMed Finds Relief Through $27M Celgene Thalidomide Deal

By Brady Huggett


Friday, January 3, 2003
EntreMed Inc. managed to resolve ongoing litigation, bring in the necessary cash to fund operations for some time and help alleviate issues surrounding a potential Nasdaq delisting through one move - the signing of a deal valued at about $27 million with Celgene Corp. for EntreMed's thalidomide analogue program. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription